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Introduction: Landiolol hydrochloride is an ultra-short-acting -blocker that is adminis-
tered intravenously and has many advantages in cardiac surgery. This study was performed to
examine the safety and eﬃcacy of low-dose landiolol continuous infusion in cardiac surgery.
Methods and Results: Nineteen patients who underwent either aortic valve replacement or
coronary artery bypass surgery received low-dose continuous infusion of landiolol
(2:8 0:75 mg/kg/min) from the time of skin incision until the second postoperative day.
Nineteen patients who did not receive landiolol served as controls. Heart rate, arterial
pressure, cardiac index, and stroke volume were measured and the occurrence of supra-
ventricular tachyarrythmia was monitored for one week after surgery. Landiolol decreased the
heart rate without causing hemodynamic deterioration. The incidence of supraventricular
tachyarrythmia was 32% and 47% in the landiolol and control groups, respectively
(P ¼ 0:50).
Conclusions: Landiolol is eﬀective for decreasing heart rate while maintaining other
hemodynamic parameters. Our data did not show a clear prophylactic eﬀect of landiolol on
postoperative supraventricular tachyarrythmia.
(J Arrhythmia 2011; 27: 57–62)
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Introduction
Landiolol hydrochloride is an ultra-short-acting
intravenous -blocker that was developed in Japan.1)
Since landiolol has strong 1-receptor aﬃnity and
high cardioselectivity, it has a reduced eﬀect on
blood pressure and is less likely to cause broncho-
spasm. The elimination half-life of landiolol is 4
minutes, which is also advantageous in cardiac
surgery.1–3) The eﬃcacy of landiolol for intraoper-
ative and postoperative supraventricular tachyarryth-
mia (SVT) has been demonstrated in cardiac surgery
and in other procedures.4–10) However, the dose of
landiolol has diﬀered among these studies and has
not been clearly determined. Postoperative SVT
occurs in 11–40% of patients in coronary artery
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bypass grafting and in over 50% of patients after
valvular surgery, and can lead to hemodynamic
deterioration or thromboembolic complications.11)
Thus methods for the prevention of postoperative
SVT are necessary. We hypothesized that landiolol
suppression of the -receptor stimulation caused by
operative stress would reduce postoperative SVT. In
this study, the safety and eﬃcacy of low-dose
continuous infusion of landiolol were assessed by
evaluation of perioperative hemodynamics and oc-
currence of SVT during the week after surgery.
Methods
Nineteen patients in our hospital received low-
dose continuous infusion of landiolol starting from
the time of skin incision until the second post-
operative day (landiolol group) between April 2008
and February 2009. Nineteen patients who were not
treated with landiolol during the same period served
as controls (control group). Landiolol administration
was used for patients with a heart rate (HR) over
80 bpm after induction of anesthesia. This study
was performed in a non-randomized basis. SVT was
deﬁned as supra-ventricular arrhythmias, including
atrial ﬁbrillation (af), atrial ﬂutter (AF), and parox-
ysmal supra-ventricular tachycardia, in this study.
There were no diﬀerences in the patient character-
istics between the two groups (Table 1). Exclusion
criteria included a history of SVT, A-V block, sick
sinus syndrome, severe peripheral arterial disease
and bronchial asthma. All of the patients underwent
cardiac surgery, which was limited to isolated aortic
valve replacement (AVR) or isolated coronary artery
bypass grafting (CABG) under cardio-pulmonary
bypass or an oﬀ-pump procedure (OPCAB). All
operations were performed as scheduled. The oper-
ative characteristics are shown in Table 2.
All patients received hydroxyzine hydrochloride
(0.5mg/kg) and atropine sulfate (0.5mg) intramusc-
ularly 30 minutes before entering the operating
room. Anesthesia was induced with midazolam (0.1
mg/kg) and fentanyl (0.1mg), and tracheal intuba-
tion was facilitated with vecuronium bromide (0.1
mg/kg). After intubation, an arterial cannula was
inserted into the radial artery and a Swan-Ganz
catheter was inserted into the main pulmonary
artery through the left subclavian vein. Anesthesia
was maintained with additional fentanyl (0.1mg),
vecuronium bromide, propofol (50mg/hour) and
isoﬂurane. Landiolol administration was used for
patients with HR over 80 bpm after induction of
anesthesia. Landiolol was started at the time of skin
incision at an initial dose of less than 5 mg/kg/min,
which is much lower than that recommended in the
standard guidelines for the administration of land-
iolol in Japan.3) No initial loading or bolus injection
was administered. The dose of landiolol was ad-
justed to keep the HR between 70 and 90 bpm.
Table 1 Patient characteristics
Landiolol group
n ¼ 19
Control group
n ¼ 19 P-value
Age 69 12 71 9 NS
Female 7 6 NS
BSA 1.58  0.18 1.66  0.21 NS
HT 11 12 NS
DM 3 2 NS
HL 8 7 NS
EF (%) 66 10 65 12 NS
-blocker 1 2 NS
Digitalis 1 1 NS
BSA: body surface area, HT: hypertension, DM: diabetes
mellitus, HL: hyperlipidemia, EF: ejection fraction by
echocardiography, NS: not signiﬁcant
Table 2 Operative characteristics
Landiolol group
n ¼ 19
Control group
n ¼ 19 P-value
AVR 4 4 NS
CABG 10 10 NS
OPCAB 5 5 NS
Operation time (min.) 166 47 161 40 NS
Intubation time (min.) 204 89 193 188 NS
Blood transfusion in OR 4 6 NS
Blood transfusion in ICU 2 5 NS
Drainage in 12hrs. (ml.) 267 128 245 106 NS
ICU Stay (day) 2.1  0.3 2.1  0.5 NS
AVR: aortic valve replacement, CABG: coronary artery bypass grafting, OPCAB: oﬀ-pump coronary artery bypass, OR:
operation room, ICU: intensive care unit, NS: not signiﬁcant
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Continuous infusion was terminated on the morning
of the second postoperative day (POD). Oral -
blockers were not used routinely after termination of
landiolol.
HR and arterial pressure (AP) were recorded at 8
time points: before administration of landiolol (T1),
5 minutes after administration (T2), 15 minutes after
administration (T3), at the end of the operation (T4),
at ICU arrival (T5), at extubation (T6), on POD1
(T7), and on POD2 (T8) in the landiolol group. For
the control group, time point T1 corresponded to
before skin incision, and T2 and T3 corresponded to
5 and 15 minutes after the skin incision, respectively.
Cardiac index (CI) and stroke volume (SV) were
recorded in the landiolol group from T1 to T7, before
the Swan-Ganz catheter was removed on POD1.
Dopamine, dobutamine and nitroglycerin were ad-
ministered (all at 5ml/hr) from the time of com-
pletion of the main procedure and were terminated
on POD1. The occurrence of postoperative SVT was
monitored continuously by electrocardiogram (ECG)
for 7 days in the landiolol and control groups. SVT
that continued for over 3 minutes was considered as
postoperative SVT. Administration of postoperative
SVT was determined by the surgeon in charge.
Our institutional research ethics board approved
the study and waived the requirement for individual
consent. Data are expressed as the means  standard
deviation. Diﬀerences between groups were exam-
ined using a Student t test and a Fisher exact test using
StatView 5.0 software (SAS Institute Inc., Cary, NC,
USA). A p value of<0:05was considered signiﬁcant.
Results
1. Safety and efﬁcacy
The initial dose of landiolol was 2:8 0:75
mg/kg/min and the maintenance dose was 2:6
0:97 mg/kg/min. HR decreased signiﬁcantly in the
landiolol group at T3 and was thereafter maintained
at the target rate (Figure 1). HR increased signiﬁ-
cantly in the control group at all time points
compared with T1. There were no diﬀerences in
the HR between the two groups except at T1.
When the change of HR was expressed as a ratio
(T2-T8/T1), the ratios were 1:01 0:07 in the
landiolol group and 1:34 0:04 in the control group
(P < 0:01). Systolic AP decreased signiﬁcantly in
the landiolol group at T2 and T3, respectively,
whereas CI increased signiﬁcantly (Figures 2, 3).
SV did not show any signiﬁcant changes in the
landiolol group. Systolic AP increased signiﬁcantly
at T2 and T3 compared with T1 in the control group.
There were diﬀerences of systolic AP at T1-3
between the landiolol and control groups. After
T4 the hemodynamic parameters ﬂuctuated at var-
ious time points, but these variations were con-
sidered to be most likely due to the operative
procedures and postoperative changes in hemody-
namic conditions. Importantly, none of the patients
required termination of landiolol administration
earlier than scheduled due to adverse eﬀects, and
no hemodynamic deterioration occurred during land-
iolol infusion over the total administration time of
42:2 8:9 h.
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Figure 1 Changes in heart rate.
The heart rates in the landiolol group at T1 and T3 were 83 12 and 73 18 bpm, respectively (P ¼ 0:04).
There were no statistically signiﬁcant changes of HR in the landiolol group compared with T1, except at T3.
Heart rate increased signiﬁcantly in the control group at T2-8. There were no diﬀerences between the two
groups, except at T1. P < 0:01 compared with the landiolol and control groups at T1.
P < 0:01 compared with T1 and each time point in the control group.
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2. Prevention of postoperative SVT
Postoperative SVT occurred in 6 patients (32%) in
the landiolol group and in 9 (47%) in the control
group (P ¼ 0:50). Postoperative SVT was caused by
atrial ﬁbrillation (af) in all cases in the landiolol
group, and occurred after AVR in 1 case, OPCAB in
2 cases, and CABG in 3 cases. Postoperative SVT
occurred in 2 patients during the period of continuous
landiolol infusion (11%) and in 4 patients (21%) after
landiolol termination on POD2. Treatment for af was
necessary in 5 patients in the landiolol group. While
all patients recovered to sinus rhythm, direct-current
(DC) delivery was required in 1 patient; the details
are shown in Table 3. In the control group, the types
of postoperative SVT were atrial ﬂutter in 1 case,
PSVT in 1 case, and af in 7 cases; and SVT occurred
after AVR in 4 cases, OPCAB in 1 case, and CABG
in 4 cases. Treatment was necessary in 7 patients and
landiolol was administered as the ﬁrst line drug in 6
of these cases; these details are also shown in Table 3.
Sinus rhythm recovered in 3 of the 6 patients as a
result of treatment with landiolol alone. While
ultimately all patients recovered to sinus rhythm,
DC was required in 1 patient.
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Figure 2 Changes in systolic arterial pressures.
Systolic AP values decreased signiﬁcantly in the landiolol group were from T2 to T8, compared with T1. These
changes were statistically signiﬁcant but remained insigniﬁcant clinically. The systolic AP in the control group
was increased at T2 and T3 compared with T1. P ¼ 0:02 compared with the landiolol and control groups
at T1.
P < 0:01 compared with T1 and each of the time points in the landiolol group.
P < 0:05 compared with T1 and each of the time points in the control group.
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Figure 3 Changes in cardiac index.
CI values at T1 and T3 were 2:2 0:3 and 2:7 7:8L/min/BSA, respectively (P ¼ 0:02).
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Discussion
Landiolol hydrochloride is an ultra-short-acting
injectable -blocker that has many advantages for
perioperative use in cardiac surgery, and successful
treatment of perioperative tachyarrythmia with
landiolol has been reported in a variety of clinical
settings.4–10) Postoperative SVT is common after
cardiac surgery, with a reported incidence ranging
from 11–40% after coronary bypass grafting and
over 50% after valvular surgery. Previous reports
have suggested that af is associated with an in-
creased incidence of congestive heart failure, renal
insuﬃciency, and stroke, all of which prolong
hospitalization and increase the rate of rehospitali-
zation after discharge.11) While the causes of post-
operative af are unclear, arrhythmogenic risk factors
may include pericardial inﬂammation or eﬀusion,
excessive production of catecholamines and auto-
nomic imbalance, and interstitial mobilization of
ﬂuid with resultant changes in volume and pres-
sure.11) A history of af, older age, concomitant
valvular heart disease, cardiopulmonary bypass, and
myocardial protection are risk factors for postoper-
ative atrial arrhythmia.12)
We hypothesized that continuous -blockade
against the excessive catecholamine release caused
by surgical stress may reduce the occurrence
of postoperative tachyarrythmia. The level of
surgical stress is greater in the intraoperative
and early postoperative periods. Mathew et al.
showed that new onset of af after cardiac surgery
was most common on POD2 and recurrence was
most common on POD3 in a large population
of patients.12) Since we removed the intravenous
infusion line on the morning of POD2 to facilitate
postoperative rehabilitation, we decided that this
was an appropriate time to stop the continuous
infusion of landiolol.
The dose of landiolol used in the study was
determined based on our extensive experience of the
use of landiolol for postoperative SVT. However, we
also wanted to conﬁrm the eﬃcacy and safety of
low-dose continuous infusion of landiolol, since the
dose selected and administration protocol has not
been used in previous studies.3–10) In these studies,
the dose of landiolol has ranged from 4.7 to 40
mg/kg/min under diﬀerent clinical situations.3–10)
However, we have found that landiolol is eﬀective
for postoperative SVT at doses ranging from 2 to
5 mg/kg/min. Therefore, landiolol can be eﬀective
at doses lower than that recommended in the
standard guidelines.3) In fact, the dose of landiolol
in our study was the lowest of all those cited in
the literature, but was suﬃcient to control HR.
Furthermore, although landiolol was initiated during
surgery when there is excessive intrinsic release of
catecholamines, HR decreased signiﬁcantly within
15 minutes, even at the low dose. This rapid onset
of action of landiolol, even without initial loading or
bolus infusion, is an attractive property in cardio-
vascular surgery. Regarding safety, the signiﬁcant
decreases in systolic AP after 5 minutes and diastolic
AP after 15 minutes were thought to be related to the
surgical procedure, because SV and CI were main-
tained during these periods. Premature termination
of landiolol was not necessary in any of the patients,
and many studies have also supported the safety of
landiolol, which has a higher 1-selectvity than other
-blockers that are currently available.4–10)
The occurrence of postoperative SVT was lower
in the landiolol group compared with the control
group, but the diﬀerence was not statistically
signiﬁcant. However, postoperative SVT during the
continuous infusion of landiolol was suppressed
Table 3 Occurrence of postoperative SVT and treatment
Landiolol group
Case Age Gender Operation POD SVTtype Treatment
1 78 M OPCAB 1 af Mg, P, C
2 82 F AVR 2 af Landiolol
3 68 M CABG 2 af SR
4 76 M CABG 2 af Landiolol, DC
5 86 F OPCAB 2 af C
6 77 M CABG 7 af P
Control group
Case Age Gender Operation POD SVTtype Treatment
1 81 F AVR 2 af Landiolol
2 73 M CABG 3 af Landiolol, C
3 76 F CABG 3 af Landiolol, DC
4 72 M OPCAB 3 af Landiolol, C
5 85 M AVR 4 af Landiolol, C
6 76 F AVR 6 PSVT SR
7 60 M CABG 6 AF Landiolol
8 75 F CABG 6 af P
9 74 M AVR 7 af SR
SVT: supraventricular tachyarrythmia, OPCAB: oﬀ-pump
coronary artery bypass, AVR: aortic valve replacement,
CABG: coronary artery bypass graft, af: atrial ﬁbrillation,
PSVT: paroxysmal supra-ventricular tachycardia, AF:
atrial ﬂutter, Mg: magnesium, P: pilsicainide, C: carvedi-
lol, SR: spontaneous recovery, DC: direct-current cardio-
version
SVT occurred during continuous infusion of landiolol.
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signiﬁcantly. In this study prophylactic medication
for SVT was not used and only clinically signiﬁcant
postoperative SVT was treated. In the landiolol
group, postoperative SVT occurred in 2 patients
during continuous landiolol infusion. These cases
were treated with incremental doses of landiolol, but
this was not successful in 1 patient. Therefore, there
may be another cause of SVT that is unresponsive to
-blocker therapy.11) Postoperative SVT also occur-
red in 4 patients in the landiolol group after ter-
mination of landiolol on POD2, which may be due to
the rapid oﬀset of action of landiolol, as well as its
rapid onset. Therefore, our data do not support that
landiolol infusion from the intraoperative period to
the early postoperative period has any sustained
prophylactic eﬀect on postoperative SVT after ter-
mination of landiolol infusion. In the control group,
postoperative SVT occurred in 9 patients and
was treated in 7. Landiolol was administered as the
ﬁrst line drug in 6 of these patients and was eﬀective
in 3.
A previous clinical study has shown that occur-
rence of af after cardiovascular surgery was signiﬁ-
cantly lower in patients who received postoperative
landiolol (17%) than in those who did not (40%).6)
However, our ﬁndings do not clearly show a
preventive eﬀect of landiolol on SVT after termi-
nation of landiolol, and a further study of the dose and
duration of continuous landiolol infusion will be
necessary to examine this issue. The clinical beneﬁts
of the prophylactic preoperative and postoperative
use of oral -blockers have been demonstrated in
large clinical studies.13–15) In normal clinical practice,
prophylactic postoperative -blockers are routinely
used in patients with risk factors for SVT. Therefore,
in a future study we plan to determine whether
prophylactic oral -blocker therapy in addition to
continuous infusion of perioperative -blockers can
reduce the occurrence of postoperative SVT.
Conclusions
Low-dose continuous infusion of landiolol de-
creased heart rate while maintaining hemodynamic
parameters in patients after cardiac surgery. While
postoperative SVT was suppressed during low-dose
continuous infusion of landiolol, no prophylactic
eﬀect of landiolol on postoperative SVT was
evident. The major limitations of the study were
the small number of patients and the inclusion of
three diﬀerent types of cardiac procedures.
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